InterVenn Biosciences Announces the Publication of Early Detection of Advanced Adenoma and Colorectal Cancer in Gastroenterology, the Flagship Journal of the American Gastroenterological Association

InterVenn’s Serum Glycoproteome Profiling resulted in Sensitivities of 90.9% for Advanced Adenoma without High Grade Dysplasia, 85.7% for Advanced Adenoma with High Grade Dysplasia and 89.8% for all stages of Colorectal Cancer in discovery study.